Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Huang

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|July 3, 2010
Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazinesJacob A Kaizerman, Wade Aaron, Songzhu An, et al.
Journal of Medicinal Chemistry|September 1, 2020
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine ProductionXiaohui Du, Jared Moore, Brian R Blank, et al.
Bioorganic & Medicinal Chemistry Letters|August 16, 2011
Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hitMatthew L Brown, Wade Aaron, Richard J Austin, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonistsBrian S Lucas, Wade Aaron, Songzhu An, et al.
Journal of Medicinal Chemistry|October 26, 2025
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor ImmunosuppressionJared T Moore, Hiroyuki Kawai, Brian R Blank, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|July 3, 2010
Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazinesJacob A Kaizerman, Wade Aaron, Songzhu An, et al.
Journal of Medicinal Chemistry|September 1, 2020
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine ProductionXiaohui Du, Jared Moore, Brian R Blank, et al.
Bioorganic & Medicinal Chemistry Letters|August 16, 2011
Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hitMatthew L Brown, Wade Aaron, Richard J Austin, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonistsBrian S Lucas, Wade Aaron, Songzhu An, et al.
Journal of Medicinal Chemistry|October 26, 2025
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor ImmunosuppressionJared T Moore, Hiroyuki Kawai, Brian R Blank, et al.
Pageof 3